Commercial Model Innovation Key To Lowering China Compliance Risks
This article was originally published in PharmAsia News
Balanced scorecards, big data, and platform strategies are among the new tools being employed by pharma companies ramping up compliance and lowering risks in China, where market access remains challenging and pricing pressures persistent. Such commercial model innovation should also improve physician interaction while providing new medical solutions, said executives at a recent RDPAC gathering in Beijing.
You may also be interested in...
2016 Review: Pricing, R&D Issues Dominate China Commercial Arena
2016 was again another busy year on the commercial front in China, with market changes, new regulations, and ongoing pricing pressures all affecting the pharma sector. Meanwhile, the push for licensing deals, innovation, and international expansion continued apace.
Chinese Biopharma Tycoons Down But Not Out In Latest Global Billionaire Ranking
China continues to dominate the latest list of global billionaires and top execs from domestic pharma firms Hengrui and Hansoh ranked among the wealthiest overall in the country, along with the founder of vaccine maker Zhifei Bio. A number of top Chinese biopharma business executives also featured in the global top 100 billionaires list.
COVID Lessons Mean New Vaccine Approach Needed In China, Exec Says
CEO of Chinese vaccine developer BravoVax shares views with Scrip on pandemic lessons learned and new approaches needed to move forward.